Pneumolysin with low hemolytic activity confers an early growth advantage to streptococcus pneumoniae in the blood

Infection and Immunity

Volumn 79, Issue 10, 2011, Pages 4122-4130

  Harvey, Richard M ^a   Ogunniyi, Abiodun D ^a   Chen, Austen Y ^a   Paton, James C ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOLYSIN;

ALLELE; ANIMAL CELL; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM MUTANT; BLOOD; CELL ISOLATION; CELL MUTANT; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIDEMIC; FEMALE; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, OUTBRED STRAINS; BACTEREMIA; BACTERIAL PROTEINS; BLOOD; FEMALE; HEMOLYSIS; HUMANS; IMMUNIZATION; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PNEUMOCOCCAL INFECTIONS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; VIRULENCE;

EID: 80855127655     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05418-11     Document Type: Article

References (36)

1. Alexander, J. E., et al. 1994. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect. Immun. 62:5683-5688.
2. Arévalo, M. T., et al. 2009. Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunol. Med. Microbiol. 55:346-351.
3. Benton, K. A., M. P. Everson, and D. E. Briles. 1995. A pneumolysinnegative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect. Immun. 63:448-455.
4. Berry, A. M., et al. 1995. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect. Immun. 63:1969-1974.
5. Berry, A. M., J. Yother, D. E. Briles, D. Hansman, and J. C. Paton. 1989. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect. Immun. 57:2037-2042.
6. Braun, J. S., R. Novak, G. Gao, P. J. Murray, and J. L. Shenep. 1999. Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect. Immun. 67:3750-3756.
7. Brueggemann, A. B., and B. G. Spratt. 2003. Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates. J. Clin. Microbiol. 41:4966-4970.
8. Cockeran, R., et al. 2001. Proinflammatory interactions of pneumolysin with human neutrophils. J. Infect. Dis. 183:604-611.
9. Douce, G., K. Ross, G. Cowan, J. Ma, and T. J. Mitchell. 2010. Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae. Vaccine 28:3231-3237.
10. Giammarinaro, P., and J. C. Paton. 2002. Role of RegM, a homologue of the catabolite repressor protein CcpA, in the virulence of Streptococcus pneumoniae. Infect. Immun. 70:5454-5461.
11. Harvey, R. M., et al. 2011. A Variable region within the genome of Streptococcus pneumoniae contributes to strain-strain variation in virulence. PLoS One 6:e19650.
12. Horton, R. M., et al. 1993. Gene splicing by overlap extension. Methods Enzymol. 217:270-279.
13. Houldsworth, S., P. W. Andrew, and T. J. Mitchell. 1994. Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect. Immun. 62:1501-1503.
14. Jefferies, J. M., et al. 2007. Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks. J. Infect. Dis. 196:936-944.
15. Jounblat, R., A. Kadioglu, T. J. Mitchell, and P. W. Andrew. 2003. Pneumococcal behavior and host responses during bronchopneumonia are affected differently by the cytolytic and complement-activating activities of pneumolysin. Infect. Immun. 71:1813-1819.
16. Kadioglu, A., et al. 2000. Host cellular immune response to pneumococcal lung infection in mice. Infect. Immun. 68:492-501.
17. Kirkham, L. A., et al. 2006. Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin. J. Clin. Microbiol. 44:151-159.
18. Kirkham, L. A., et al. 2006. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect. Immun. 74:586-593.
19. Littmann, M., et al. 2009. Streptococcus pneumoniae evades human dendritic cell surveillance by pneumolysin expression. EMBO Mol. Med. 1:211-222.
20. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
21. Lock, R. A., Q. Y. Zhang, A. M. Berry, and J. C. Paton. 1996. Sequence variation in the Streptococcus pneumoniae pneumolysin gene affecting haemolytic activity and electrophoretic mobility of the toxin. Microb. Pathog. 21:71-83.
22. Malley, R., et al. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. U. S. A. 100:1966-1971.
23. Martin, B., P. Garcia, M. P. Castanie, B. Glise, and J. P. Claverys. 1995. The recA gene of Streptococcus pneumoniae is part of a competence-induced operon and controls an SOS regulon. Dev. Biol. Stand. 85:293-300.
24. McAllister, L. J., et al. 2004. Molecular analysis of the psa permease complex of Streptococcus pneumoniae. Mol. Microbiol. 53:889-901.
25. McNeela, E. A., et al. 2010. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog. 6:e1001191.
26. Mitchell, T. J., P. W. Andrew, F. K. Saunders, A. N. Smith, and G. J. Boulnois. 1991. Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein. Mol. Microbiol. 5:1883-1888.
27. Morona, J. K., D. C. Miller, R. Morona, and J. C. Paton. 2004. The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneumoniae . J. Infect. Dis. 189:1905-1913.
28. Morona, J. K., J. C. Paton, D. C. Miller, and R. Morona. 2000. Tyrosine phosphorylation of CpsD negatively regulates capsular polysaccharide biosynthesis in Streptococcus pneumoniae. Mol. Microbiol. 35:1431-1442.
29. O'Brien, K. L., et al. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893-902.
30. Ogunniyi, A. D., R. L. Folland, D. E. Briles, S. K. Hollingshead, and J. C. Paton. 2000. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect. Immun. 68:3028-3033.
31. Ogunniyi, A. D., P. Giammarinaro, and J. C. Paton. 2002. The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo. Microbiology 148:2045-2053.
32. Paton, J. C., R. A. Lock, and D. J. Hansman. 1983. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect. Immun. 40:548-552.
33. Paton, J. C., et al. 1991. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect. Immun. 59:2297-2304.
34. Paton, J. C., B. Rowan-Kelly, and A. Ferrante. 1984. Activation of human complement by the pneumococcal toxin pneumolysin. Infect. Immun. 43:1085-1087.
35. Weiser, J. N., R. Austrian, P. K. Sreenivasan, and H. R. Masure. 1994. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect. Immun. 62:2582-2589.
36. Witzenrath, M., et al. 2011. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J. Immunol. 187:434-440.